Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice
Accumulating evidence has indicated the presence of mature miRNAs in the nucleus, but their effects on steatohepatitis remain elusive. We have previously demonstrated that the intranuclear miR-204-3p in macrophages protects against atherosclerosis, which shares multiple risk factors with metabolic dysfunction-associated steatotic liver disease (MASLD). Herein, we aimed to explore the functional significance of miR-204-3p in steatohepatitis. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 5, 2024 Category: Gastroenterology Authors: Zhaowei Zou, Xiu Liu, Jie Yu, Tao Ban, Ziyi Zhang, Peiqi Wang, Renli Huang, Fuxin Zheng, Yafei Chang, Wanli Peng, Yubo Tang, Xiaoqing Feng, Ziying Zhao, Xiaofei Lv, Shuai Huang, Jiawei Guo, Yonghua Tuo, Zhijun Zhou, Sijia Liang Tags: Research Article Source Type: research
Systemic metabolic Abnormalities: Key drivers of complications and mortality in MASLD
This study was funded by the the National Key Research and Development Program of China (2021YFA0805100); the National Natural Science Foundation of China grant nos. 82200659 (XF); and the Natural Science Foundation of Shandong Province grant no. ZR2022QH002 (XF) (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 2, 2024 Category: Gastroenterology Authors: Xiude Fan, Bofei Zhang, Yingzhou Shi, Luna Liu, Jiajun Zhao Tags: Letter to the Editor Source Type: research
Reply to: “Longitudinal changes in fatty liver index are associated with risk of hepatocellular carcinoma: A nationwide cohort study in Korea”
The evolving role of serial non-invasive tests in predicting HCC in MASLD (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 1, 2024 Category: Gastroenterology Authors: George Cholankeril, Fasiha Kanwal Tags: Letter to the Editor Source Type: research
Treating autoimmune hepatitis – More science, more progress, better therapy
People living with autoimmune diseases frequently have impaired quality and quantity of life, and usually a chronic disease course.1 Physicians usually focus on their own areas of interest but taking the ‘patient helicopter’ view is important to challenge our current management paradigms. Patients may fairly ask what do autoimmune hepatitis (AIH), rheumatoid arthritis, multiple sclerosis, psoriasis, and inflammatory bowel diseases have in common? All are immune-mediated diseases, whose exact aet iology is unknown, all may lead to acute flares that can be effectively managed by corticosteroid therapy, all require long-t...
Source: Journal of Hepatology - February 1, 2024 Category: Gastroenterology Authors: Gideon M. Hirschfield, Ansgar W. Lohse Tags: Editorial Source Type: research
HIV coinfection exacerbates HBV-induced liver fibrogenesis through a HIF-1 α- and TGF-β1-dependent pathway
Persons with chronic hepatitis B virus (HBV) infection coinfected with HIV experience accelerated progression of liver fibrosis compared to those with HBV mono-infection. We hypothesize that HIV and its proteins promote HBV-induced liver fibrosis in HIV/HBV coinfected cell culture models through HIF-1 α and TGF-β1 signaling. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 1, 2024 Category: Gastroenterology Authors: Min Xu, Charlotte Warner, Xiaoqiong Duan, Zhimeng Cheng, Andre J. Jeyarajan, Wenting Li, Yongtao Wang, Tuo Shao, Shadi Salloum, Pei-Jer Chen, Xu Yu, Raymond T. Chung, Wenyu Lin Tags: Research Article Source Type: research
Editorial: Treating Autoimmune Hepatitis – more science, more progress, better therapy
GMH has consulted for Intercept, Advanz, Ipsen, Cymabay, Pliant, Mirum, GSK, Kowa; AWL occasional lecture fees from Falk Pharma; consulting for investigational drugs and trial design for Genfit, Merck and Roche. Coordinator of the European Reference Network for Hepatological Diseases (ERN RARE-LIVER). (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 1, 2024 Category: Gastroenterology Authors: Gideon M. Hirschfield, Ansgar W. Lohse Tags: Editorial Source Type: research
The Evolving Role of Serial Non-Invasive Tests in Predicting HCC in MASLD
The letter to the editor by Kang et al. provides insightful data into the association between longitudinal changes in Fatty Liver Index (FLI), a non-invasive test (NIT) that measures steatosis, and the incidence of hepatocellular carcinoma (HCC) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD, previously referred to as nonalcoholic fatty liver disease or NAFLD). This evidence aligns with our findings, 1 which support the integration of serial NIT measurements of liver disease severity as a means to risk stratify and surveil the growing population affected by MASLD. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 1, 2024 Category: Gastroenterology Authors: George Cholankeril, Fasiha Kanwal Tags: Letter to the Editor Source Type: research
Reply to: “The impact of infections on the onset of contrast-associated acute kidney injury in patients with cirrhosis”
We thank Tergast et al. for taking inspiration from our recently issued manuscript about the risk of contrast-induced acute kidney injury (CI-AKI) in patients with cirrhosis1 in order to re-analyse their previously published data.2 Tergast et al.2 previously analysed a large retrospective cohort of patients with dec ompensated cirrhosis and ascites, suggesting that contrast-enhanced computed tomography (CECT) is not associated with an increased risk of AKI. They now reviewed their data to assess the impact of concomitant infections on the risk of CI-AKI. (Source: Journal of Hepatology)
Source: Journal of Hepatology - January 31, 2024 Category: Gastroenterology Authors: Daniela Campion, Gian Paolo Caviglia, Carlo Alessandria Tags: Letter to the Editor Source Type: research
Familial clustering of MASLD: Rethinking Strategies for Population Screening
This study, which looked into whether there is a familial cluster of adverse liver-related outcomes, stands out for its comprehensive approach and the valuable insights provided. Researchers discovered a specific familial clustering of adverse liver-related outcomes in families of people with MASLD-associated fibrosis and identified at-risk populations could guide the development of preventative or therapeutic strategies. (Source: Journal of Hepatology)
Source: Journal of Hepatology - January 31, 2024 Category: Gastroenterology Authors: Qiaoyue Ge, Zhenmi Liu Tags: Letter to the Editor Source Type: research
Distinction of Autoimmune Hepatitis from Drug Induced Autoimmune Like Hepatitis: The Answer Lies at the Interface
Ahmad Alkashash: data acquisition, data analysis, drafting manuscript. (Source: Journal of Hepatology)
Source: Journal of Hepatology - January 31, 2024 Category: Gastroenterology Authors: Ahmad Alkashash, Xin Zhang, Raj Vuppalanchi, Craig Lammert, Romil Saxena Tags: Letter to the Editor Source Type: research
Navigating the Landscape of Liver Cancer Management: Study Designs in Clinical Trials and Clinical Practices
Randomized controlled trials (RCTs) represent the gold standard for evidence generation across all areas of medicine and especially in the oncology field, as they allow unbiased estimates of treatment effect without confounders. Observational studies have many problems that could reduce their internal and external validity. However, large prospective (well-conducted) observational real-world studies (RWS) can detect the occurrence of rare adverse events or monitoring for long-term adverse events. (Source: Journal of Hepatology)
Source: Journal of Hepatology - January 31, 2024 Category: Gastroenterology Authors: Giuseppe Cabibbo, Ciro Celsa, Lorenza Rimassa, Ferran Torres, Jordi Rimola, Roman Kloeckner, Jordi Bruix, Calogero Camm à, Maria Reig Tags: Review Source Type: research
Mycophenolate mofetil for the induction of remission in primary biliary cholangitis with predominant features of autoimmune hepatitis
This study was funded by grants from the 135 project for disciplines of excellence, West China Hospital, Sichuan University (No. (Source: Journal of Hepatology)
Source: Journal of Hepatology - January 31, 2024 Category: Gastroenterology Authors: Xiaoli Fan, Fan Yang, Leyu Zhou, Li Yang Tags: Letter to the Editor Source Type: research
Reply to “The impact of infections on the onset of contrast-associated acute kidney injury in patients with cirrhosis”
None. (Source: Journal of Hepatology)
Source: Journal of Hepatology - January 31, 2024 Category: Gastroenterology Authors: Daniela Campion, Gian Paolo Caviglia, Carlo Alessandria Tags: Letter to the Editor Source Type: research
An in-depth exploration of new clinical and prognostic characteristics of decompensated liver cirrhosis patterns
I would like to share my ideas on the publication “A new clinical and prognostic characterization of the patterns of decompensation of cirrhosis.” Marta Tonon et al. recruited a total of 617 outpatients with cirrhosis from two Italian tertiary centers (Padua and Milan) from January 2003 to June 2021 and followed prospectively until the end of t he study, death or liver transplantation.1 It is the first investigation into the role of non-acute decompensation (NAD) in patients with liver cirrhosis, which is both timely and of great significance. (Source: Journal of Hepatology)
Source: Journal of Hepatology - January 31, 2024 Category: Gastroenterology Authors: Zhongxing Ning Tags: Letter to the Editor Source Type: research
Reply to: “ARID3A variant and the risk of primary biliary cholangitis in a Central European cohort”
We thank Dr. Krawczyk and his colleagues for the interest in our work and for the efforts to validate the role of AT-rich interaction domain 3A (ARID3A) in primary biliary cholangitis (PBC) using a large Central European cohort.1 (Source: Journal of Hepatology)
Source: Journal of Hepatology - January 30, 2024 Category: Gastroenterology Authors: Ruqi Tang, You Li, Ruiling Chen, Xiong Ma Tags: Letter to the Editor Source Type: research
